|
|
|
|
|
|
Drug Highest PhaseDiscovery |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target- |
Mechanism- |
Active Org.- |
|
Active Indication- |
|
Drug Highest PhaseDiscontinued |
First Approval Ctry. / Loc.- |
First Approval Date- |
|
MechanismProtease inhibitors |
Active Org.- |
|
Active Indication- |
|
Drug Highest PhaseDiscontinued |
First Approval Ctry. / Loc.- |
First Approval Date- |
Open, single-arm phase-III study to investigate the percutaneous absorption of abafungin after topical dermal application of Abafungin cream 1.0 % (YORK Pharma GmbH) in 20 patients with tinea pedis interdigitalis
Phase III study to evaluate the anti-mycotic efficacy of a topical Abafungin formulation in patients with tinea pedis - N.A.
Phase II dose ranging study to evaluate the anti-mycotic efficacy of topical Abafungin formulations in patients with tinea pedis. - N.A.
100 Clinical Results associated with York Pharma Gmbh
0 Patents (Medical) associated with York Pharma Gmbh
100 Deals associated with York Pharma Gmbh
100 Translational Medicine associated with York Pharma Gmbh